Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 132K 122K 114K 214K 14.59M 217K 1.44M 561K 7.1M 576K 563K 24.53M	P/E Ratio 2014	-0.87x	P/E Ratio 2015	-1.04x
Enterprise Value	20.01M 17.24M 15.89M 14.88M 27.94M 1.9B 28.3M 188M 73.12M 926M 75.09M 73.49M 3.2B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
21/12/18	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
11/01/18	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
27/09/16	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
30/08/16	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
11/08/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
09/07/16	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
08/06/16	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
30/03/16	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
23/03/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
22/03/16	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/11/15	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.41%	+0.14%	+38.28%	+153.06%	1,010B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.32%	+49.09%	580B
ABBVIE INC.	+1.32%	+0.22%	+19.18%	+67.17%	402B
ROCHE HOLDING AG	+0.77%	0.00%	+21.28%	+16.70%	330B
NOVARTIS AG	+0.44%	+3.48%	+25.65%	+35.66%	281B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.54%	+14.67%	280B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.35%	-47.35%	197B
AMGEN INC.	+0.32%	+1.61%	+20.32%	+59.80%	192B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+14.19%	+61.12%	156B
Average	+0.23%	+0.84%	+18.93%	+45.54%	380.99B
Weighted average by Cap.	-0.23%	+1.04%	+27.77%	+70.41%

	2014	2015
Net sales	-	-
Net income	-38.52M -33.19M -30.58M -28.64M -53.78M -3.66B -54.46M -361M -141M -1.78B -145M -141M -6.16B	-6.84M -5.9M -5.43M -5.09M -9.56M -651M -9.68M -64.18M -25.01M -317M -25.69M -25.14M -1.09B
Net Debt	-45K -38.78K -35.73K -33.46K -62.83K -4.28M -63.63K -422K -164K -2.08M -169K -165K -7.2M	19.86M 17.11M 15.77M 14.77M 27.72M 1.89B 28.08M 186M 72.55M 919M 74.51M 72.93M 3.18B

Star Scientific, Inc. Stock Nasdaq

Stocks

US85517P1012

Pharmaceuticals

Valuation: Star Scientific, Inc.

Latest news : Star Scientific, Inc.

Analysts' recommendations: Star Scientific, Inc.

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq Other stock markets
- ^USD	-